To navigate the following site navigation expect to utilize the tab key to move through items sequentially. The spacebar or enter keys can be utilized to interact with items that open sub-navigation.
When autocomplete results are available use up and down arrows to review and enter to select.
The Pulmonary Fibrosis Foundation Patient Registry will collect data on at least 2,000
patients with interstitial lung disease (ILD) at approximately 40 clinical sites in the US.
The Registry is targeting enrollment of approximately 60% of the 2,000 ILD participants to
have idiopathic pulmonary fibrosis (IPF). The aim of the Registry is to create a cohort of
well-characterized patients with interstitial lung disease (ILD) for participation in
retrospective and prospective research
Recruitment Criteria
Accepts Healthy Volunteers
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms
No
Study Type
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.
An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.
Searching Both is inclusive of interventional and observational studies.
Observational [Patient Registry]
Eligible Ages
18 Years - 99 Years
Gender
All
More Inclusion & Exclusion Criteria
Inclusion Criteria:
1. 18 years old or older. 2. Understand and sign the informed consent document. 3. ILD Diagnosis must be made / confirmed at a participating Registry center.
1. The diagnostic evaluation must include, at a minimum, a medical history, physical
examination, pulmonary function testing and a computerized tomography (CT) scan
of the chest.
2. If patients exhibit another pulmonary disease (such as emphysema or asthma), the
primary disease must be ILD.
4. Anticipated additional follow up at the Registry center within one year.
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.
Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.
Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.
Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.
Lead Sponsor
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.
University of Michigan
Principal Investigator
The person who is responsible for the scientific and technical direction of the entire clinical study.
Kevin R Flaherty, MD
Principal Investigator Affiliation
University of Michigan
Agency Class
Category of organization(s) involved as sponsor (and collaborator) supporting the trial.
Other
Overall Status
Recruiting
Countries
United States
Conditions
The disease, disorder, syndrome, illness, or injury that is being studied.
The Pulmonary Fibrosis Foundation Patient Registry will collect data on at least 2,000
patients with interstitial lung disease (ILD) at approximately 40 clinical sites in the US.
The Registry is targeting enrollment of approximately 60% of the 2,000 ILD participants to
have idiopathic pulmonary fibrosis (IPF). The aim of the Registry is to create a cohort of
well-characterized patients with interstitial lung disease (ILD) for participation in
retrospective and prospective research.
Patients who meet inclusion and exclusion criteria and are being treated at a Registry site
can be asked to participate. Patients will be required to read and sign an Institutional
review board(IRB)-approved informed consent document prior to any Registry activity taking
place.
At the time of informed consent, participants will be asked to indicate if they are
interested in being contacted by Registry site personnel for potential participation in
future clinical trials and/or studies. Participants who opt out will not be contacted for
future studies.
No clinical procedures, testing, or diagnostics will be required by virtue of Registry
participation. Participants will permit Registry staff to abstract clinical data obtained as
part of routine clinical care in the diagnosis and treatment of ILD. These data will be
entered into a web-based, electronic data capture (EDC) by the Registry staff to at regular
intervals. Some of these data will be retrospective, having been collected prior to
consenting for the Registry.
Computed tomography (CT) images collected for diagnosis and / or treatment will be
de-identified at the Registry site and uploaded to a secure server that is a 21 Code of
Federal Regulations (CFR) Part 11, Good Clinical Practice (GCP), and HIPAA compliant online
imaging repository.
Participants will be asked to complete patient reported outcome (PRO) surveys related to ILD
symptoms and quality of life at the time of enrollment and during clinical follow-up
visits.Participants who are not seen for clinical follow-up within 12 months will be
contacted by telephone or mail by Registry site personnel to complete the PRO measures.
The University of Michigan Statistical Analysis of Biomedical and Educational Research
(SABER) unit will serve as the Registry Data Coordinating Center and will manage data entered
into a web based, CFR 21 Part 11 compliant electronic data capture (EDC) system by the
Registry sites.
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
University fo Alabama at Birmingham, Birmingham, Alabama